Movement Alert｜Ascentage Pharma Rises 5.42% in Regular Trading, Biotech Sector Rallies on Post-ASCO Momentum and RSU Share Purchases

Market Focus

Jun 12

On June 12, Ascentage Pharma rose 5.42% in regular trading, reaching HK$35.28/share with turnover of HK$52.76 million, rebounding from a 52-week low of HK$32.50 touched earlier in the week.

The rally comes amid a broad biotech sector recovery and multiple company-specific catalysts. On June 10 and 11, the company's trustee purchased a combined 300,000 shares on-market for the 2022 Restricted Share Unit Plan, signaling management confidence. Additionally, Ascentage's ASCO 2026 presentations continue to draw attention, including oral abstract-level data on its APG-115 combined with lisaftoclax (APG-2575) in pediatric solid tumors — the first clinical validation globally of the MDM2-p53 plus BCL-2 dual apoptosis pathway.

Within the Biotechnology sector, multiple peers posted gains: AKESO up 7.0%, SKB BIO up 8.77%, INNOVENT BIO up 4.59%, 3SBIO up 3.88%, and BEIGENE up 1.87%, reflecting sector-wide recovery following the post-ASCO pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1111716399"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111716399\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111716399?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 11:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111716399","market":"us","top_or_hot":-1,"title":"Movement Alert｜Ascentage Pharma Rises 5.42% in Regular Trading, Biotech Sector Rallies on Post-ASCO Momentum and RSU Share Purchases","media":"Market Focus","content":"<p><p>On June 12, Ascentage Pharma rose 5.42% in regular trading, reaching HK$35.28/share with turnover of HK$52.76 million, rebounding from a 52-week low of HK$32.50 touched earlier in the week.</p><p>The rally comes amid a broad biotech sector recovery and multiple company-specific catalysts. On June 10 and 11, the company's trustee purchased a combined 300,000 shares on-market for the 2022 Restricted Share Unit Plan, signaling management confidence. Additionally, Ascentage's ASCO 2026 presentations continue to draw attention, including oral abstract-level data on its APG-115 combined with lisaftoclax (APG-2575) in pediatric solid tumors — the first clinical validation globally of the MDM2-p53 plus BCL-2 dual apoptosis pathway.</p><p>Within the Biotechnology sector, multiple peers posted gains: AKESO up 7.0%, SKB BIO up 8.77%, INNOVENT BIO up 4.59%, 3SBIO up 3.88%, and BEIGENE up 1.87%, reflecting sector-wide recovery following the post-ASCO pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Ascentage Pharma Rises 5.42% in Regular Trading, Biotech Sector Rallies on Post-ASCO Momentum and RSU Share Purchases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Ascentage Pharma Rises 5.42% in Regular Trading, Biotech Sector Rallies on Post-ASCO Momentum and RSU Share Purchases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-12 11:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 12, Ascentage Pharma rose 5.42% in regular trading, reaching HK$35.28/share with turnover of HK$52.76 million, rebounding from a 52-week low of HK$32.50 touched earlier in the week.</p><p>The rally comes amid a broad biotech sector recovery and multiple company-specific catalysts. On June 10 and 11, the company's trustee purchased a combined 300,000 shares on-market for the 2022 Restricted Share Unit Plan, signaling management confidence. Additionally, Ascentage's ASCO 2026 presentations continue to draw attention, including oral abstract-level data on its APG-115 combined with lisaftoclax (APG-2575) in pediatric solid tumors — the first clinical validation globally of the MDM2-p53 plus BCL-2 dual apoptosis pathway.</p><p>Within the Biotechnology sector, multiple peers posted gains: AKESO up 7.0%, SKB BIO up 8.77%, INNOVENT BIO up 4.59%, 3SBIO up 3.88%, and BEIGENE up 1.87%, reflecting sector-wide recovery following the post-ASCO pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药","start_time":0,"source_url":"","article_id":"1111716399","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111716399","pubTimestamp":1781235132,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 12, Ascentage Pharma rose 5.42% in regular trading, reaching HK$35.28/share with turnover of HK$52.76 million, rebounding from a 52-week low of HK$32.50 touched earlier in the week.The rally...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药"},"translate_title":"动态警报|亚盛医药常规交易上涨5.42%，生物科技板块因ASCO后势头和RSU股票购买而上涨","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"On June 12, Ascentage Pharma rose 5.42% in regular trading, reaching HK$35.28/share with turnover of HK$52.76 million, rebounding from a 52-week low of HK$32.50 touched earlier in the week.The rally comes amid a broad biotech sector recovery and multiple company-specific catalysts. On June 10 and 11, the company's trustee purchased a combined 300,000 shares on-market for the 2022 Restricted Share Unit Plan, signaling management confidence. Additionally, Ascentage's ASCO 2026 presentations continue to draw attention, including oral abstract-level data on its APG-115 combined with lisaftoclax (APG-2575) in pediatric solid tumors — the first clinical validation globally of the MDM2-p53 plus BCL-2 dual apoptosis pathway.Within the Biotechnology sector, multiple peers posted gains: AKESO up 7.0%, SKB BIO up 8.77%, INNOVENT BIO up 4.59%, 3SBIO up 3.88%, and BEIGENE up 1.87%, reflecting sector-wide recovery following the post-ASCO pullback.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}